Breaking News

Tweet TWEET

Increased Demand, Fast Track Designations, and Strong Sales Boost Revenue Growth - Research Report on Alexion, Baxter

  Increased Demand, Fast Track Designations, and Strong Sales Boost Revenue
 Growth - Research Report on Alexion, Baxter International, Align Technology,
                             Transition, and OPKO

Editor Note: For more information about this release, please scroll to bottom

PR Newswire

NEW YORK, July 23, 2013

NEW YORK, July 23, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Alexion
Pharmaceuticals Inc. (NASDAQ: ALXN), Baxter International Inc. (NYSE: BAX),
Align Technology, Inc. (NASDAQ: ALGN), Transition Therapeutics Inc. (NASDAQ:
TTHI), and OPKO Health Inc. (NYSE: OPK). Today's readers may access these
reports free of charge - including full price targets, industry analysis and
analyst ratings - via the links below.

Alexion Pharmaceuticals Inc. Research Report

On July 16, 2013, Alexion Pharmaceuticals Inc. (Alexion) announced that the
Company's first-in-class terminal complement inhibitor, Soliris (eculizumab)
has received a positive opinion for orphan medicinal product designation from
the Committee for Orphan Medical Products (COMP) of the European Medicines
Agency (EMA) for the treatment of neuromyelitis optica (NMO), a
life-threatening, ultra-rare neurological disorder. An orphan medicinal
product status, granted by the European Commission, provides incentives to
develop medicinal products to treat, prevent, or diagnose diseases or
conditions that affect no more than five in 10,000 persons in the EU. The
proposed status would provide Alexion with certain benefits and incentives,
including a period of marketing exclusivity. According to the Company, the
positive opinion of the COMP has now been forwarded to the European Commission
for final approval and publication in the community register. The Full
Research Report on Alexion Pharmaceuticals Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at: [http://www.analystscorner.com/r/full_research_report/4619_ALXN]

--

Baxter International Inc. Research Report

On July 18, 2013, Baxter International Inc. (Baxter International) announced
its financial results for Q2 2013. Worldwide sales of the Company increased 3%
YoY to $3.7 billion. According to the Company, BioScience sales rose 6% YoY on
constant currency basis and 5% on actual basis to $1.6 billion, due to
improved demand for the Company's hemophilia therapies, including ADVATE
[Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method] and FEIBA (an
inhibitor therapy) as well as accelerated growth of select plasma-based
therapeutics and vaccines. The Company reported Medical Products sales of $2.0
billion, reflecting 1% growth, driven primarily by gains in peritoneal
dialysis patients, as well as growth of certain injectable therapies and
anesthesia products. Further, the Company reported net income of $590 million
or $1.07 per diluted share compared to net income of $661 million or $1.19 per
diluted share in Q2 2012. These results include after-tax special items
totaling $49 million ($0.09 per diluted share) primarily for costs associated
with Baxter's planned acquisition of Gambro AB. Q2 2013 results also included
a net after-tax benefit from special items totaling $42 million of income
($0.07 per diluted share). The Full Research Report on Baxter International
Inc. - including full detailed breakdown, analyst ratings and price targets -
is available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/163d_BAX]

--

Align Technology, Inc. Research Report

On July 18, 2013, Align Technology Inc. (Align Technology) reported its
financial results for Q2 2013. Total net revenues increased 6.6% QoQ to $163.8
million, with Invisalign clear aligner revenues increasing 8.3% QoQ to $153.3
million. Net profit was $29.3 million or $0.36 per diluted share compared to
net loss of $42 million or $0.52 per diluted share in Q1 2013 and net profit
of $28.5 million or $0.34 in Q2 2012. Commenting on the results, Thomas M.
Prescott, President and Chief Executive Officer of Align Technology, said,
"Strong second quarter results were driven by higher Invisalign volumes and
ASPs, with sequential growth across all customer channels." The Full Research
Report on Align Technology, Inc. - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/69b3_ALGN]

--

Transition Therapeutics Inc. Research Report

On July 17, 2013, Transition Therapeutics Inc. (Transition) announced that the
US Food and Drug Administration (FDA) granted Fast Track Designation to the
development program for ELND005, which was submitted for the treatment of
Neuropsychiatric Symptoms (NPS) in Alzheimer's disease (AD). According to the
Company, ELND005 is an orally bioavailable small molecule that is being
investigated by Transition's licensing partner, Elan Corporation plc (Elan),
for multiple neuropsychiatric indications on the basis of its proposed dual
mechanism of action, which includes β-amyloid anti-aggregation and regulation
of brain myo-inositol levels. Elan will be responsible for all development and
commercialization activities as well as costs of ELND005. The Full Research
Report on Transition Therapeutics Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at: [http://www.analystscorner.com/r/full_research_report/09eb_TTHI]

--

OPKO Health Inc. Research Report

On July 16, 2013, OPKO Health Inc. (OPKO) announced the appointment of David
Okrongly, Ph.D. as the President of the Company's Diagnostics Business Unit.
According to OPKO, Dr. Okrongly brings extensive experience developing and
commercializing advanced diagnostic platforms. Prior to his involvement with
OPKO, Dr. Okrongly served as the Chief Operating Officer of Exosome
Diagnostics, Inc., where he was responsible for establishing product,
platform, and regulatory strategy for the Company's proprietary technology for
purifying RNA derivatives from exosomes. Phillip Frost, M.D., Chairman and
Chief Executive Officer of OPKO, said, "David's profound industry knowledge
will be invaluable as we near the U.S. commercial launch for our 4Kscore
prostate cancer diagnostic test, advance the development of our point of care
diagnostic platform, and continue to execute our strategy of establishing
industry-leading positions in large and rapidly growing medical markets." The
Full Research Report on OPKO Health Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at: [http://www.analystscorner.com/r/full_research_report/cd43_OPK]

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by a CFA. However, we are only human and are prone to
    make mistakes. If you notice any errors or omissions, please notify us
    below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider has, through Chartered Financial
Analysts, only reviewed the information provided by Equity News Network in
this article or report according to the Procedures outlined by Equity News
Network. Equity News Network is not entitled to veto or interfere in the
application of such procedures by the outsourced provider to the articles,
documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

http://www.analystscorner.com

SOURCE Analysts' Corner

Contact: CONTACT PERSON: Joe Thomas - CONTACT PHONE: +1-310-496-8071 (North
America)
 
Press spacebar to pause and continue. Press esc to stop.